Semantic Concept Synthesis Method Patented by Primal Fusion

USPTO granted Patent US12596741B2 to Primal Fusion Inc. on April 7, 2026. The patent covers methods for semantic concept definition and relationship synthesis using machine learning techniques. Inventors include Peter Sweeney and Alexander David Black, with the patent application filed on June 14, 2024.

System and Method for Protecting Information - US12596823B2

USPTO granted Patent US12596823B2 to Microsoft Technology Licensing, LLC on April 7, 2026. The patent covers AI and machine learning methods for protecting sensitive information from unauthorized disclosure in model processing. The 20-claim patent (CPC: G06N 20/00) describes a system that detects sensitive information in AI model outputs and verifies whether input content supported that inclusion.

Environment detection and optimization for an information handling system

USPTO granted Dell Products L.P. Patent No. US12596825B2 for an information handling system that uses sensor-based inferences to detect a user's environment and control access to confidential information using behavior analysis. The patent, filed January 26, 2024, with 18 claims, covers technology for implementing content-based information protection in various environments including public places.

Systems and methods for merchant level fraud detection based in part on event timing

USPTO granted Patent US12597035B2 to Stripe, LLC for a fraud detection system that analyzes merchant transaction timing using machine learning models. The patent covers encoding merchant system data and time-based sequential operation data into inputs for multiple ML models to generate fraud scores. When fraud thresholds are met, remediative actions are triggered against merchant transactions or systems.

Real-time facial restoration and relighting in videos using facial enhancement neural networks

The USPTO granted Microsoft Technology Licensing, LLC patent US12597096B2 covering an image restoration system that enhances low-quality video images in real-time using neural networks. The technology combines autoencoder models with distortion classifiers to dynamically re-light and restore faces captured under low-light conditions. The patent includes 20 claims.

Macrocyclic ULK1/2 inhibitors for cancer treatment

The USPTO has granted patent US12594277B2 to the Sal k Institute for Biological Studies covering macrocyclic ULK1/2 inhibitors and their therapeutic applications. The patent includes 8 claims directed to compounds and methods for treating cancer using ULK-mediated diseases. The patent expires April 2026 with a February 2021 filing date.

Capsid inhibitors for the treatment of HIV

The USPTO granted Patent US12594267B2 to Gilead Sciences, Inc. covering capsid inhibitor compounds of Formula (Ia) and (Ib) for treating HIV infections in heavily treatment-experienced patients with multidrug resistant HIV. The patent includes 13 claims and lists inventors Anna Chiu, Charles William Rowe, and Scott P. Sellers.

Hyaluronic acid pluronic hydrogel for articular cartilage treatment

USPTO granted Patent US12594297B2 to Medicrinia, Co., Ltd. on April 7, 2026, covering a hydrogel composition of hyaluronic acid and pluronic for preventing or treating articular and cartilage injury. The patent has 9 claims, CPC classifications A61K 31/728, A61K 9/06, A61K 47/36, A61P 19/02, and was filed on August 3, 2020.

Method for enhancing pharmacokinetics using P450 inhibitors with piperidine carboxylate

USPTO granted Takeda Pharmaceutical patent US12594269B2 covering compositions comprising methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof combined with cytochrome P450 inhibitors to enhance pharmacokinetics and plasma concentration. The patent, containing 18 claims, is assigned to Takeda Pharmaceutical Company Limited with inventors including Mark Rogge, Hélène Faessel, Hong Lu, and others.

Methods of treating Fabry disease in patients having a mutation in the GLA gene

USPTO granted Amicus Therapeutics Patent No. US12594268B2 covering methods of treating Fabry disease using pharmacological chaperones for α-galactosidase A in patients with GLA gene mutations. The patent includes 9 claims and was filed on January 16, 2019. This IP protection grants Amicus Therapeutics exclusive rights to these therapeutic methods for the rare genetic disorder.